Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 12/20 | 0.49 |
| ▸ | METAP1 | P53582 | 10/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487741 | 1.00 | METAP2 (0.49) | METAP2METAP1ALDH1A1CYP2C19HPGD | |
| SCHEMBL6487731 | 1.00 | METAP2 (0.49) | METAP2METAP1ALDH1A1CYP2C19HPGD | |
| SCHEMBL7068948 | 0.85 | METAP2 (0.39) | METAP2METAP1CYP2C19HPGDHSD17B10 | |
| SCHEMBL6477113 | 0.84 | METAP2 (0.67) | METAP2METAP1ALPLGAASMN1; SMN2 | |
| SCHEMBL6478812 | 0.80 | METAP2 (0.47) | METAP2METAP1ALDH1A1CYP2C19HPGD | |
| SCHEMBL6477893 | 0.80 | METAP2 (0.47) | METAP2METAP1ALDH1A1CYP2C19HPGD | |
| SCHEMBL6476461 | 0.69 | METAP2 (0.68) | METAP2METAP1HPGDHSD17B10ALPL | |
| SCHEMBL6478032 | 0.69 | METAP2 (0.69) | METAP2METAP1ALDH1A1HPGDKMT2A | |
| SCHEMBL6477297 | 0.68 | METAP2 (0.77) | METAP2METAP1 | |
| SCHEMBL6486428 | 0.68 | METAP2 (0.66) | METAP2METAP1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | claimed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | claimed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885ALDH1A1 583/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885ALDH1A1 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.